SEHK:1696

Stock Analysis Report

Executive Summary

Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical and minimally invasive treatment systems in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa.

Snowflake

Fundamentals

Excellent balance sheet and fair value.


Similar Companies

Share Price & News

How has Sisram Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.8%

1696

1.3%

HK Medical Equipment

2.2%

HK Market


1 Year Return

1.1%

1696

8.1%

HK Medical Equipment

-1.3%

HK Market

Return vs Industry: 1696 underperformed the Hong Kong Medical Equipment industry which returned 8.1% over the past year.

Return vs Market: 1696 exceeded the Hong Kong Market which returned -1.3% over the past year.


Share holder returns

1696IndustryMarket
7 Day-3.8%1.3%2.2%
30 Day9.6%-1.0%-2.9%
90 Day14.2%19.0%-5.8%
1 Year3.7%1.1%9.3%8.1%2.3%-1.3%
3 Yearn/a10.9%7.5%15.6%3.9%
5 Yearn/a3.3%-1.8%20.1%0.06%

Price Volatility Vs. Market

How volatile is Sisram Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sisram Medical undervalued based on future cash flows and its price relative to the stock market?

36%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: 1696 (HK$4.58) is trading below our estimate of fair value (HK$7.12)

Significantly Undervalued: 1696 is trading below fair value, but not by a significant amount.


Price Based on Earnings

PE vs Industry: 1696 is good value based on its PE Ratio (10.9x) compared to the Medical Equipment industry average (15.7x).

PE vs Market: 1696 is poor value based on its PE Ratio (10.9x) compared to the Hong Kong market (10.3x).


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate 1696's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: 1696 is good value based on its PB Ratio (0.8x) compared to the HK Medical Equipment industry average (1.6x).


Next Steps

Future Growth

How is Sisram Medical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: 1696's forecast earnings growth (15.9% per year) is above the savings rate (2%).

Earnings vs Market: 1696's earnings (15.9% per year) are forecast to grow faster than the Hong Kong market (11.2% per year).

High Growth Earnings: 1696's earnings are forecast to grow, but not significantly.

Revenue vs Market: Insufficient data to determine if 1696's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 1696's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if 1696's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sisram Medical performed over the past 5 years?

30.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 1696's earnings have grown significantly by 30.2% per year over the past 5 years.

Accelerating Growth: 1696's earnings growth over the past year (64.2%) exceeds its 5-year average (30.2% per year).

Earnings vs Industry: 1696 earnings growth over the past year (64.2%) exceeded the Medical Equipment industry 50.2%.


Return on Equity

High ROE: 1696's Return on Equity (7.6%) is considered low.


Return on Assets

ROA vs Industry: 1696's Return on Assets is below or equal to the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: 1696's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Sisram Medical's financial position?


Financial Position Analysis

Short Term Liabilities: 1696's short term assets ($196.9M) exceeds its short term liabilities ($41.4M)

Long Term Liabilities: 1696's short term assets (196.9M) exceeds its long term liabilities (25.5M)


Debt to Equity History and Analysis

Debt Level: 1696's debt to equity ratio (0.9%) is considered satisfactory

Reducing Debt: Insufficient data to determine if 1696's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 1696's debt is well covered by operating cash flow (735.9%).

Interest Coverage: 1696 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: 1696 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 1696's debt is covered by short term assets (assets are 66.608590x debt).


Next Steps

Dividend

What is Sisram Medical's current dividend yield, its reliability and sustainability?

2.23%

Current Dividend Yield


Dividend Yield vs Market

company2.2%marketbottom25%2.3%markettop25%6.3%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: 1696's dividend (2.23%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.25%).

High Dividend: 1696's dividend (2.23%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.35%).

Stable Dividend: Too early to tell whether 1696's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if 1696's dividend payments are increasing as they only just started paying a dividend.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (24.2%), 1696's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Sisram Medical's salary, the management and board of directors tenure and is there insider trading?

1.6yrs

Average management tenure


CEO

Lior Dayan (49yo)

2.3yrs

Tenure

US$884,000

Compensation

Mr. Lior Moshe Dayan has been Chief Executive Officer and Executive Director at Sisram Medical Ltd since June 6, 2017 and is responsible for its overall and day-to-day management and development. Mr. Dayan ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Lior's total compensation is reasonable compared to companies of similar size in the Hong Kong market.

Compensation vs Earnings: Lior's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.6yrs

Average Tenure

50.5yo

Average Age

Experienced Management: 1696's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Age and Tenure

2.2yrs

Average Tenure

44.5yo

Average Age

Experienced Board: 1696's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$308,37216 Jul 19
Lior Dayan
EntityIndividual
Role
Chief Executive Officer
CEO & Executive Director
Shares77,500
Max PriceUS$3.98

Ownership Breakdown


Management Team

  • Susan Lo (61yo)

    Company Secretary

    • Tenure: 2.3yrs
  • Liu Yi (43yo)

    Executive Chairman

    • Tenure: 3.5yrs
  • Lior Dayan (49yo)

    CEO & Executive Director

    • Tenure: 2.3yrs
    • Compensation: US$884.00k
  • Avraham Farbstein (64yo)

    Chief Strategy Officer

    • Tenure: 1.6yrs
  • Ran Ezioni (52yo)

    Chief Operating Officer

    • Tenure: 1.5yrs
  • Guojun Bu (43yo)

    CFO & Executive Director

    • Tenure: 0.8yrs

Board Members

  • Addy Fong (60yo)

    Independent Non-Executive Director

    • Tenure: 2.2yrs
    • Compensation: US$25.00k
  • Yifang Wu (50yo)

    Non-Executive Director

    • Tenure: 3yrs
  • Yao Wang (46yo)

    Non-Executive Director

    • Tenure: 3.5yrs
  • Liu Yi (43yo)

    Executive Chairman

    • Tenure: 3.5yrs
  • Lior Dayan (49yo)

    CEO & Executive Director

    • Tenure: 2.3yrs
    • Compensation: US$884.00k
  • Leo Chan (40yo)

    Independent Non-Executive Director

    • Tenure: 2.2yrs
    • Compensation: US$25.00k
  • Jenny Chen (40yo)

    Independent Non-Executive Director

    • Tenure: 2.2yrs
    • Compensation: US$25.00k
  • Kenneth Liu (49yo)

    Independent Non-Executive Director

    • Tenure: 2.2yrs
    • Compensation: US$25.00k
  • Guojun Bu (43yo)

    CFO & Executive Director

    • Tenure: 0.8yrs
  • Dai Kun (42yo)

    Non-Executive Director

    • Tenure: 0.2yrs

Company Information

Sisram Medical Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sisram Medical Ltd
  • Ticker: 1696
  • Exchange: SEHK
  • Founded: 2013
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: HK$2.043b
  • Shares outstanding: 442.16m
  • Website: https://www.sisram-medical.com

Number of Employees


Location

  • Sisram Medical Ltd
  • 14 Halamish Street
  • Caesarea Industrial Park
  • Caesarea
  • 38900
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1696SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDSep 2017

Biography

Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical and minimally invasive treatment systems in the Asia Pacific, Europe, North Amer ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 12:54
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)